Multi-Centre Study of Intraurethral Valve-Pump Catheter in Women with a Hypocontractile or Acontractile Bladder

Chen, T.Y.-H.; Ponsot, Y; Carmel, Maude; Bouffard, Nicole A.; Kennelly, Michael; Tu, Le-Mai

doi:10.1016/j.eururo.2005.04.020

Cited by 14 publications

(6 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The caveats are the same as with the treatment of overactive bladder. Replaceable remote‐controlled intraurethral prosthesis for women with underactive bladder have been recently approved by the FDA; these do not require surgery, increase quality of life, and reduce the risk of urinary complications, although the experience in patients with MSA is still limited (Fig. ).…”

Section: Urinary Dysfunctionmentioning

confidence: 99%

Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies

2018

View full text Add to dashboard Cite

Dysfunction of the autonomic nervous system afflicts most patients with Parkinson disease and other synucleinopathies such as dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure, reducing quality of life and increasing mortality. For example, gastrointestinal dysfunction can lead to impaired drug pharmacodynamics causing a worsening in motor symptoms, and neurogenic orthostatic hypotension can cause syncope, falls, and fractures. When recognized, autonomic problems can be treated, sometimes successfully. Discontinuation of potentially causative/aggravating drugs, patient education, and nonpharmacological approaches are useful and should be tried first. Pathophysiology-based pharmacological treatments that have shown efficacy in controlled trials of patients with synucleinopathies have been approved in many countries and are key to an effective management. Here, we review the treatment of autonomic dysfunction in patients with Parkinson disease and other synucleinopathies, summarize the nonpharmacological and current pharmacological therapeutic strategies including recently approved drugs, and provide practical advice and management algorithms for clinicians, with focus on neurogenic orthostatic hypotension, supine hypertension, dysphagia, sialorrhea, gastroparesis, constipation, neurogenic overactive bladder, underactive bladder, and sexual dysfunction. © 2018 International Parkinson and Movement Disorder Society.

show abstract

Section: Urinary Dysfunctionmentioning

confidence: 99%

Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies

2018

View full text Add to dashboard Cite

show abstract

“…The median percent improvement from baseline was 54% for inFlow users. There were no unanticipated, serious, or long‐lasting adverse events in this study . The inFlow device remains available and in use in the United States.…”

Section: Managementmentioning

confidence: 82%

“…The pivotal clinical trial for inflow recruited 273 women with impaired detrusor contractility using CIC, of which 157 were enrolled to receive the inflow device . There were a total of 74 women that withdrew from the study, most commonly citing discomfort ( n = 34; 32.4%) or leakage ( n = 29; 27.6%) as a reason for withdrawal, leaving a total of 77 subjects that completed the protocol.…”

Section: Managementmentioning

confidence: 99%

“…The pivotal clinical trial for inflow recruited 273 women with impaired detrusor contractility using CIC, of which 157 were enrolled to receive the inflow device. 39 There were a total of 74 women that withdrew from the study, most commonly citing discomfort (n = 34; 32.4%) or leakage (n = 29; 27.6%) as a reason for withdrawal, leaving a total of 77 subjects that completed the protocol. This study found 98% of evaluable subjects (113 of 115) had comparable PVRs to the control group utilizing CIC, with median PVR at each visit during inFlow treatment ranging from 10 to 20 cc, indicating noninferiority to the gold standard of CIC for bladder emptying.…”

Section: Managementmentioning

confidence: 99%

“…There were no unanticipated, serious, or long-lasting adverse events in this study. 39 The inFlow device remains available and in use in the United States. While long-term data and adverse events within a US population have not been published at the time of writing, the inFlow has been sold outside of the United States for more than a decade, mostly in Germany and Australia, without any serious adverse events reported.…”

Section: Managementmentioning

confidence: 99%

See 2 more Smart Citations

Detrusor underactivity in women: A current understanding

Hartigan

Reynolds

Dmochowski

2019

Neurourology and Urodynamics

View full text Add to dashboard Cite

Aims To examine the current understanding and management of detrusor underactivity (DUA) and underactive bladder (UAB) in women. Methods A review of the current literature was performed with a specific focus on new management strategies and treatment options for women with DUA and UAB. Results DUA has become an area of increased interest in recent years. Affecting up to 45% of older women undergoing urodynamic evaluation for non‐neurogenic lower urinary tract symptoms, DUA is common. There are a variety of possible etiologies including neurogenic or myogenic dysfunction. As there is currently no cure for DUA and no way to restore the ability of the detrusor muscle to contract, management of DUA in women is mostly focused on effective bladder drainage by urinary catheterization. Clean intermittent catheterization is the gold standard for bladder drainage however for a variety of reasons, women with DUA often are managed with indwelling urethral catheter or suprapubic tube. Medications, sacral neuromodulation, and the inFlow urinary prosthesis are also treatment alternatives or additions to catheterization. Novel therapies using stem cells and gene therapy are also under investigation for the treatment of DUA and UAB. Conclusions DUA is likely more prevalent than recognized and undertreated in women. It is vital that further research in treatment options beyond catheterization be developed for these patients to offer patients a variety of treatment options.

show abstract

Urinary catheter policies for long-term bladder drainage

Niël‐Weise

Broek

2005

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

No eligible trials were identified that compared alternative routes of catheter insertion. The data from seven trials comparing differing antibiotic policies were sparse, particularly when intermittent catheterisation was considered separately from in-dwelling catheterisation. Possible benefits of antibiotic prophylaxis must be balanced against possible adverse effects, such as development of antibiotic resistant bacteria; these cannot be reliably estimated from currently available trials.

show abstract

Multi-Centre Study of Intraurethral Valve-Pump Catheter in Women with a Hypocontractile or Acontractile Bladder

Cited by 14 publications

References 8 publications

Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies

Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies

Detrusor underactivity in women: A current understanding

Urinary catheter policies for long-term bladder drainage

Contact Info

Product

Resources

About